Roche reports positive Phase II topline data for enicepatide
Roche said it has positive topline results from CT-388-104, a Phase II trial of once-weekly enicepatide (CT-388), a dual GLP-1/GIP receptor agonist, in adults with type 2 diabetes and overweight or obesity.